BeOne Medicines (SHSE:688235) Cyclically Adjusted Book per Share: ¥25.75 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688235 BeOne Medicines Ltd SHSE:688235
77 GF Score
Price ¥276.54
GF Value ¥289.92
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines Cyclically Adjusted Book per Share?

BeOne Medicines SHSE:688235 +0.38% 77 Cyclically Adjusted Book per Share is ¥25.75 as of Mar. 2026. GuruFocus rates SHSE:688235 with a GF Score™ of 77/100 and a GF Value™ of ¥289.92 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

BeOne Medicines's adjusted book value per share for the three months ended in Mar. 2026 was ¥22.704. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ¥25.75 for the trailing ten years ended in Mar. 2026.

During the past 12 months, BeOne Medicines's average Cyclically Adjusted Book Growth Rate was 12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-22), BeOne Medicines's current stock price is ¥276.54. BeOne Medicines's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was ¥25.75. BeOne Medicines's Cyclically Adjusted PB Ratio of today is 10.74.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BeOne Medicines was 11.92. The lowest was 4.78. And the median was 8.55.


BeOne Medicines  (SHSE:688235) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BeOne Medicines's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=276.54/25.75
=10.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BeOne Medicines was 11.92. The lowest was 4.78. And the median was 8.55.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


BeOne Medicines Cyclically Adjusted Book per Share Related Terms


BeOne Medicines Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Cyclically Adjusted Book per Share Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 25.14 27.96

BeOne Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.52 28.90 27.65 27.96 25.75

SHSE:688235 vs MRNA, RPRX, ROIV: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, BeOne Medicines's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Cyclically Adjusted PB Ratio falls into.


SHSE:688235
77GF Score
BeOne Medicines Ltd SHSE:688235
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BeOne Medicines's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=22.704/108.0600*108.0600
=22.704

Current CPI (Mar. 2026) = 108.0600.

BeOne Medicines Quarterly Data

Book Value per Share CPI Adj_Book
201606 3.388 100.088 3.658
201609 2.924 99.604 3.172
201612 4.734 99.380 5.148
201703 4.100 100.040 4.429
201706 3.355 100.285 3.615
201709 8.355 100.254 9.006
201712 7.459 100.213 8.043
201803 12.151 100.836 13.022
201806 11.180 101.435 11.910
201809 17.517 101.246 18.696
201812 15.455 100.906 16.551
201903 13.904 101.571 14.792
201906 13.663 102.044 14.469
201909 11.594 101.396 12.356
201912 8.422 101.063 9.005
202003 19.587 101.048 20.946
202006 17.696 100.743 18.981
202009 24.685 100.585 26.520
202012 21.248 100.241 22.905
202103 21.771 100.800 23.339
202106 19.238 101.352 20.511
202109 17.865 101.533 19.014
202112 29.263 101.776 31.070
202203 27.975 103.205 29.291
202206 26.305 104.783 27.128
202209 24.212 104.835 24.957
202212 22.534 104.666 23.265
202303 21.023 106.245 21.382
202306 19.836 106.576 20.112
202309 20.301 106.570 20.585
202312 18.644 106.461 18.924
202403 17.815 107.355 17.932
202406 17.754 107.991 17.765
202409 17.612 107.468 17.709
202412 17.519 107.128 17.671
202503 18.078 107.722 18.135
202506 18.971 108.075 18.968
202509 20.454 107.710 20.520
202512 21.315 107.200 21.486
202603 22.704 108.060 22.704

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of ¥25.75 mean?
BeOne Medicines (SHSE:688235) has a Cyclically Adjusted Book per Share of ¥25.75 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' Cyclically Adjusted Book per Share too high?
BeOne Medicines' current Cyclically Adjusted Book per Share is ¥25.75. Overall, BeOne Medicines has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Cyclically Adjusted Book per Share compare to MRNA and RPRX?
BeOne Medicines' Cyclically Adjusted Book per Share of ¥25.75 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Cyclically Adjusted Book per Share is ¥25.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (SHSE:688235) is currently considered Fairly Valued. The stock's GF Value™ is ¥289.92, compared to a current price of ¥276.54 — trading 4.6% below its estimated fair value. The current Cyclically Adjusted Book per Share is ¥25.75. BeOne Medicines' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For BeOne Medicines (SHSE:688235), the current Cyclically Adjusted Book per Share is ¥25.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (SHSE:688235) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of ¥276.54 is trading 4.6% below its estimated GF Value™ of ¥289.92. GuruFocus considers BeOne Medicines to be Fairly Valued.

Key valuation signals for SHSE:688235:

  • Cyclically Adjusted Book per Share: ¥25.75
  • GF Value™: ¥289.92 vs. price of ¥276.54 (4.6% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688235 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
77GF Score

Get the complete analysis for SHSE:688235

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥276.54
Price
¥289.92
GF Value